These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25825185)

  • 1. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
    Pherwani N; Ghayad JM; Holle LM; Karpiuk EL
    Am J Health Syst Pharm; 2015 Apr; 72(8):619-31. PubMed ID: 25825185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
    Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
    Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
    Nguyen M; Jacobson T; Torres J; Wann A
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.
    Pettit N; Boadu D; Bischof JJ
    Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
    Ahn S; Lee YS; Lim KS; Lee JL
    Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
    Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
    Wang XJ; Chan A
    Curr Oncol Rep; 2017 Mar; 19(3):20. PubMed ID: 28271398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
    Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
    J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic.
    Cooksley T; Campbell G; Al-Sayed T; LaMola L; Berman R
    Support Care Cancer; 2018 Sep; 26(9):2937-2940. PubMed ID: 29675545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR; Durand CR; Beaulac MT; Steinberg M
    Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.
    Hwang S; Kwon KT; Kim Y; Bae S; Chang HH; Kim SW; Yoo SS; Nam SY; Baek JH
    Sci Rep; 2021 Sep; 11(1):9048. PubMed ID: 34526516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
    Nishiyama N; Takahashi S; Mizuno T; Uehara T; Hashimoto J; Kurimura Y; Masumori N
    Int J Clin Oncol; 2015 Oct; 20(5):1012-7. PubMed ID: 25652906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.